[go: up one dir, main page]

GT200500034A - Inhibidores de la proteina tirosina fosfatasa 1b - Google Patents

Inhibidores de la proteina tirosina fosfatasa 1b

Info

Publication number
GT200500034A
GT200500034A GT200500034A GT200500034A GT200500034A GT 200500034 A GT200500034 A GT 200500034A GT 200500034 A GT200500034 A GT 200500034A GT 200500034 A GT200500034 A GT 200500034A GT 200500034 A GT200500034 A GT 200500034A
Authority
GT
Guatemala
Prior art keywords
ptp1b
fosfatasa
tirosina
inhibitors
protein
Prior art date
Application number
GT200500034A
Other languages
English (en)
Inventor
Jimbo Lee
Zhao-Kui Wan
Douglas P Wilson
Bruce C Follows
Steve J Kirincich
Michael J Smith
Jun-Jun Wu
Kenneth W Foreman
David V Erbe
Yan-Ling Zhang
Weixin Xu
Steve Y Tam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500034A publication Critical patent/GT200500034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SER REFIERE A LAS PROTEINAS TIROSINA FOSFATASA (PTPASAS) TAL COMO LAS PTP1B PUEDEN JUGAR UN ROL EN LA REGULACION DE UNA AMPLIA VARIEDAD DE RESPUESTAS CELULARES TALES COMO LAS SEÑALES DE INSULINA. LOS COMPUESTOS DE TIOFENO SUSTITUIDOS TALES COMO POR EJEMPLO: TIOFENOS 2CARBOXILO, 3CARBOXIMETOXI, 5ARILO SUBSTITUIDOS, PUEDEN INHIBIR PTP1B Y DE ESA MANERA INDUCIR UNA SENSITIVIDAD MAYOR A LA INSULINA. CONSECUENTEMENTE, LA INHIBICION DE LAS PTP1B PUEDE PROPORCIONAR UN TRATAMIENTO RECIPROCO PARA LOS DESORDENES MEDIADOS POR LA PTPASA, TAL COMO LA DIABETES.
GT200500034A 2004-02-25 2005-02-24 Inhibidores de la proteina tirosina fosfatasa 1b GT200500034A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54704904P 2004-02-25 2004-02-25

Publications (1)

Publication Number Publication Date
GT200500034A true GT200500034A (es) 2005-10-31

Family

ID=34910846

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500034A GT200500034A (es) 2004-02-25 2005-02-24 Inhibidores de la proteina tirosina fosfatasa 1b

Country Status (5)

Country Link
US (1) US7521473B2 (es)
AR (1) AR047894A1 (es)
GT (1) GT200500034A (es)
TW (1) TW200602337A (es)
WO (1) WO2005081954A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203081A1 (en) * 2004-02-25 2005-09-15 Jinbo Lee Inhibitors of protein tyrosine phosphatase 1B
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US8455520B2 (en) 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
CA2716599A1 (en) * 2008-02-25 2009-09-03 Lars Thore Burgdorf Glucokinase activators
PT2373172E (pt) 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
MA32998B1 (fr) * 2009-01-30 2012-01-02 Glaxosmithkline Llc Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophényl) méthyl]éthyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide cristallin
TW201116525A (en) * 2009-07-21 2011-05-16 Gilead Sciences Inc Inhibitors of flaviviridae viruses
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
BR112012005438A2 (pt) 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
AR080001A1 (es) 2010-01-15 2012-03-07 Gilead Sciences Inc Inhibidores de virus flaviviridae
PE20121522A1 (es) 2010-01-15 2012-11-26 Gilead Sciences Inc Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
EP2734515B1 (en) 2011-07-13 2015-11-04 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
FR2993563B1 (fr) * 2012-07-20 2015-12-18 Metabrain Res Derives de thiophenes utiles dans le traitement du diabete
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
CN109790144A (zh) * 2016-04-29 2019-05-21 爱仕达生物技术有限责任公司 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
CN108239068B (zh) * 2016-12-27 2020-09-08 沈阳药科大学 一种烟酰胺类衍生物及其制备方法和用途
CN113880724A (zh) * 2021-12-06 2022-01-04 南京桦冠生物技术有限公司 一种3-(2-氨基苯基)-2-丙烯酸酯的制备方法
WO2024159176A1 (en) * 2023-01-27 2024-08-02 Contineum Therapeutics, Inc. Crystalline compound of an lpar1 antagonist

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989718A (en) * 1975-05-06 1976-11-02 Eli Lilly And Company [1]Benzothieno[3,2-b]furans
SE436037B (sv) 1976-04-30 1984-11-05 Roussel Uclaf Sett att framstella nya 11-desoxi-prostaglandin-f?712-derivat
US4877440A (en) * 1985-05-29 1989-10-31 E. I. Du Pont De Nemours And Company Thiophenesulfonamide herbicides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
DE3861268D1 (de) * 1987-07-07 1991-01-24 Shell Int Research Verfahren zur herstellung von thiophenderivaten.
GB8823040D0 (en) * 1988-09-30 1988-11-09 Lilly Sa Organic compounds & their use as pharmaceuticals
DE4014006A1 (de) 1989-04-27 1990-10-31 Schering Ag Imidazol- und triazolhaltige cyclische ketone
IE890149L (en) 1989-10-06 1990-07-19 Du Pont Sulfonylureas
CA2027022A1 (en) 1989-10-06 1991-04-07 Bruce L. Finkelstein Compounds useful for measuring low levels of sulfonylureas by immunoassay
US5086067A (en) 1989-12-18 1992-02-04 G. D. Searle & Co. Ltb4 synthesis inhibitors
US4996214A (en) * 1990-06-28 1991-02-26 Smithkline Beecham Corporation Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof
WO1993013664A2 (en) 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
EP0590885B1 (en) 1992-09-28 2000-03-15 Zeneca Limited Antibiotic carbapenem compounds
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
DE4408005A1 (de) 1993-08-11 1995-02-16 Bayer Ag Substituierte Azadioxacycloalkene
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
DE4424788A1 (de) 1993-12-22 1995-06-29 Bayer Ag Arylessigsäurederivate
WO1996002529A1 (fr) 1994-07-13 1996-02-01 Taisho Pharmaceutical Co., Ltd. Derive de l'acide thiophene acetique
GB9418762D0 (en) 1994-09-16 1994-11-02 Bayer Ag Use of substituted cyclopentane-DI-and-triones
DE4443641A1 (de) 1994-12-08 1996-06-13 Bayer Ag Substituierte Carbonsäureamide
US5686254A (en) 1995-06-07 1997-11-11 Johnson & Johnson Clinical Diagnostics, Inc. Reduction in first slide bias and improved enzyme stability by the incorporation of diaryl tellurides in thin-film immunoassay elements
US5928886A (en) * 1995-06-07 1999-07-27 Johnson & Johnson Clinical Diagnostics, Inc. Reduction in first slide bias and improved enzyme stability by incorporation of diaryl tellurides in the gravure layer of dry-film, immunoassay elements
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
WO1996040113A2 (en) 1995-06-07 1996-12-19 Sugen, Inc. Phosphatase inhibitors
US6593361B2 (en) * 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
ATE268176T1 (de) 1995-07-19 2004-06-15 Merck & Co Inc Behandlungsverfahren für darmadenome
JPH09183960A (ja) 1995-12-28 1997-07-15 Toyo Ink Mfg Co Ltd 感エネルギー線酸発生剤、感エネルギー線酸発生剤組成物および硬化性組成物
JPH09194476A (ja) 1996-01-12 1997-07-29 Taisho Pharmaceut Co Ltd チオフェンアルカン酸誘導体
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
WO1997039748A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
JP2002512628A (ja) 1997-06-13 2002-04-23 スージェン・インコーポレーテッド タンパク質チロシン酵素関連の細胞信号伝達を調節するための新規ヘテロアリール化合物
JPH1171368A (ja) 1997-08-29 1999-03-16 Masahiro Irie フォトクロミック化合物−シクロデキストリン錯体
JP2000026421A (ja) 1998-01-29 2000-01-25 Kumiai Chem Ind Co Ltd ジアリ―ルスルフィド誘導体及び有害生物防除剤
JP2004500308A (ja) 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
AU2713799A (en) 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
AU3536699A (en) 1998-04-27 1999-11-16 Ihara Chemical Industry Co. Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
US6103708A (en) * 1998-05-12 2000-08-15 American Home Products Corporation Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6221902B1 (en) * 1998-05-12 2001-04-24 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
FR2781221B1 (fr) 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
GB2343179A (en) 1998-10-26 2000-05-03 Rhone Poulenc Agrochimie Oxazinone and pyridone herbicides
WO2000027790A1 (en) 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
EP1186604A4 (en) 1999-06-16 2002-10-23 Takeda Chemical Industries Ltd Benzazepine derivatives, process for the preparation of the same and uses thereof
EP1214325B1 (en) 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
DE60118195T2 (de) 2000-07-07 2006-12-14 Novo Nordisk A/S Modulatoren von protein tyrosin phosphatasen (ptpasen)
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
WO2002018321A2 (en) 2000-08-29 2002-03-07 Abbott Laboratories Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
DE10064823A1 (de) 2000-12-22 2002-06-27 Knoll Ag Integrinrezeptorliganden
US20020147196A1 (en) * 2001-04-05 2002-10-10 Quessy Steven Noel Composition and method for treating neuropathic pain
WO2002098409A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination therapy for type ii diabetes or syndrome x
US6784173B2 (en) * 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
EP1275301A1 (en) 2001-07-10 2003-01-15 Bayer CropScience S.A. Trisubstituted heterocyclic compounds and their use as fungicides
US20040191926A1 (en) 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
JP2005509616A (ja) 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
US20050203081A1 (en) * 2004-02-25 2005-09-15 Jinbo Lee Inhibitors of protein tyrosine phosphatase 1B

Also Published As

Publication number Publication date
WO2005081954A3 (en) 2006-09-21
TW200602337A (en) 2006-01-16
AR047894A1 (es) 2006-03-01
US20050203087A1 (en) 2005-09-15
US7521473B2 (en) 2009-04-21
WO2005081954A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
GT200500034A (es) Inhibidores de la proteina tirosina fosfatasa 1b
CR20130216A (es) Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa
CL2017003496A1 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
BRPI0519383A2 (pt) sensor capacitivo de nÍvel de um lÍquido de um reservatàrio, e, reservatàrio
AR058720A1 (es) Derivados 2-feniletilamino y composicion farmaceutica
HN2002000156A (es) Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
PE20090423A1 (es) Compuestos moduladores de sirtuina
BRPI0813925A2 (pt) Utilização de pelo menos uma substância favorecendo a reversão da reação de maillard frente aos ages, método de triagem de princípios ativos favorecendo a deglicação dos ages e composição.
CL2007002867A1 (es) Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
CR9569A (es) Modificaciones cristalinas de la piraclostrobina
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
DK2150530T3 (da) Substituerede sulfonamid-derivater
CR8926A (es) Acidos de tiazolo-naftilo
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
EA201100245A1 (ru) Новый холиновый сокристалл эпалрестата
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
NO20043952L (no) Benzofuran- og benzotiofenderivater som er nyttige ved behandling av hyperproliferative forstyrrelser
PA8661701A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
JP2008506643A5 (ja) 糖尿病の治療用の血糖値低下活性成分として使用するためのホスホチロシン・ホスファターゼ１ｂ(ｐｔｐ１ｂ)阻害剤としてのジフェニルアミン置換サリチルチアゾール誘導体及び関連化合物
CL2012001485A1 (es) Compuestos derivados de benzofurano, benzooxazol y benzo[d]oxadol, como inhibidores de mek; composicion farmaceutica que los comprende, utiles en el tratamiento de enfermedades hiperproliferativas, tales como cancer e inflamacion.